Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07542548
PHASE4

D-Cycloserine for Serine Palmitoyltransferase Inhibition

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia

Official title: D-Cycloserine for Serine Palmitoyltransferase Inhibition: Treatment of a Single Patient With a Complex Hereditary Spastic Paraplegia Due to a De Novo Variant in the SPTSSA Gene

Key Details

Gender

FEMALE

Age Range

6 Years - 6 Years

Study Type

INTERVENTIONAL

Enrollment

1

Start Date

2024-07-10

Completion Date

2026-03-17

Last Updated

2026-04-21

Healthy Volunteers

No

Interventions

DRUG

D-cycloserine

Pyridoxine also prescribed to help prevent neurologic adverse events related to D-Cycloserine.

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States